Klaus Veitinger

Action Potential Venture Capital (Action Potential Venture) is a venture capital subsidiary of GlaxoSmithKline Plc founded in 2013. The firm is headquartered in London, United Kingdom.

Axon Therapies, Inc. develops treatment for heart failure. The company is headquartered in New York, NY.

MicroTransponder, Inc. develops wireless neurostimulation system for the treatment of chronic pain and other neurological indications. It is a medical device company spun out from the University of Texas at Dallas. The firm has an team of neuroengineers collaborating with academics to develop wireless solutions to treat neurological diseases. The company was founded by Lawrence James Cauller, Thomas James Curnes II and William Michael Rosellini in June 2009 and is headquartered in Austin, TX.

Neuspera Medical, Inc. is a holding company designs and manufactures neurostimulation devices. It delivers a liberating alternative treatment for certain patients trapped by the symptoms of their disease. The company was founded by Alexander Yeh and is headquartered in San Jose, CA.

SetPoint Medical Corp. operates as a biomedical technology company, which engages in the development of therapies for patients with inflammatory autoimmune diseases such as rheumatoid arthritis and Crohn?s disease. The company was founded by Kevin J. Tracey, Shaw H. Warren, and James W. Broderick in 2006 and is headquartered in Santa Clarita, CA.

Arboretum Ventures LLC (Arboretum Ventures) is a venture capital firm founded in 2002 by Jan L. Garfinkle and Tim B. Petersen. The firm is headquartered in Ann Arbor, Michigan.

Onc.ai, Inc. is a digital health company that is privately held and is developing a precision oncology care management platform. The company is based in San Carlos, CA. The company aims to transform clinical decision making and is backed by premier investment firms such as the Blue Venture Fund, MassMutual Alternative Investments, and Accomplice, among others. The company is building a pipeline of physician-centered products to fulfill the potential of precision oncology. The company was founded by Akshay Nanduri, who has been the CEO since incorporation.